Avicanna's Pharma Pivot: From Canadian Medical Cannabis to Global Biopharma Ambitions
Approaching EBITDA breakeven, a U.S. listing path, and a deeper pipeline mark a strategic turn.
AVCN.TO · Earnings Call · 2026-04-07
Financial Turning Point
2025 was the year Avicanna stopped losing money at the adjusted EBITDA line, achieving a loss of just under $300,000 versus $1.0 million in 2024. Revenue held steady at $25.5 million, but gross profit margin expanded from 48% to 53%, driven by higher-margin service and licensing revenue and a growing mix of branded products on its MyMedi platform. The balance sheet carries zero structured debt. As CEO Aras Azadian put it, “we were able to substantially improve our adjusted EBITDA to less than $300,000 for all of 2025” — Aras Azadian, CEO, Founder · 2026-04-07. This is a company that has essentially weaned itself off external capital—only $1 million raised last year versus $4.8 million in 2024. The financial narrative is shifting from survival to scale, and the language on the call reflects that. Avicanna now describes itself as a biopharma company, not just a cannabis cultivator, a subtle but significant repositioning that sets the stage for a different kind of investor.International Expansion and the U.S. Bet
The most concrete change is the geographic footprint. Trunerox, the company's first pharmaceutical product for catastrophic pediatric epilepsy, received marketing authorization in Colombia and launched softly in Q1 2026. This is the first commercial pharma product, a proof point for the regulatory pathway in emerging markets. Meanwhile, Avicanna began direct CBD sales into the United States through the re+PLAY brand, using its own organic CBD and CBG sourced from Colombia. And exports to Australia and Europe have opened, giving the company a presence in 24 international markets. The CEO framed this as a platform that can scale without heavy capex: “we are operating in a very asset-light model where we believe that the formulations products can enter more and more international markets” — Aras Azadian, CEO, Founder · 2026-04-07. The company is aggressively pursuing a international market strategy, but the real prize is the United States. Management has now “engaged in discussions to be able to build our U.S. listing pathway in terms of a senior exchange” — Aras Azadian, CEO, Founder · 2026-04-07, a move that would reposition Avicanna as a U.S.-listed pharma company. This is coupled with the expectation of federal cannabis rescheduling, which the CEO believes will open the door to healthcare/biotech investment. The prior year's call had already hinted at this direction, with Aras saying “there is a potential for this company to be a $1 billion company” — Aras Azadian, Chief Executive Officer · 2025-04-22 and envisioning a meaningful exit within three years. That ambition is now being operationalized through a concrete listing plan.Pipeline as the Ultimate Value Driver
Beneath the commercial expansion, Avicanna is investing more in its scientific platform. The company finalized two self-emulsifying drug delivery systems—in fluid and PwdRX—which are designed to improve bioavailability and speed of onset for oral cannabinoid products. These are being translated into next-generation 3.0 formats in Canada, including fast-acting capsules and gummies. The clinical pipeline is also advancing: a Phase II randomized placebo-controlled trial in osteoarthritic pain is in recruitment, and a Phase I dose-finding study for anxiety, approved by Health Canada, is slated to begin. real world evidence remains a cornerstone, with a national observational study published in the Canadian Journal of Pain showing significant improvements across multiple endpoints. This evidence generation is what differentiates Avicanna from typical Canadian LP peers, and it directly supports the pharma positioning. The CEO stressed that this is where the long-term value lies: “we believe that this will ultimately drive the real value of the company in the future” — Aras Azadian, CEO, Founder · 2026-04-07. The combination of proprietary drug delivery technology, clinical data, and a medical platform is the moat.Stock Overhang and the Case for Re-rating
Despite the operational progress, the stock has been under pressure. The CEO candidly acknowledged on the call:He attributed this to an oversupply of shares from a major shareholder in a relatively illiquid TSX listing. This is a supply-side drag that the company hopes to counteract with the U.S. listing and the rescheduling catalyst. The prior year's call had already telegraphed the goal of an acquisition, with Aras saying “there is a potential for this company to be a $1 billion company” — Aras Azadian, Chief Executive Officer · 2025-04-22 and projecting an exit within three years. Now the strategy is to become a U.S.-listed biopharma company that can attract a wider investor base and potentially a pharmaceutical acquirer. The company's evolution from a Canadian medical cannabis purveyor to an international pharma player is unmistakable. The financials are near breakeven, the pipeline is deepening, and the regulatory winds in the U.S. could provide a powerful tailwind. The key risk remains the stock overhang and execution risks in new markets, but the direction is clear: Avicanna is no longer just a cannabis company—it's a specialty pharma in the making.Unfortunately, we're seeing the inverse impact of our financial and corporate and clinical and R&D progress in terms of the stock price.